Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12209857 | 0.84 | NAMPT (0.45) | PTPN11NAMPTCYP17A1PSMB8EGLN2 | |
| SCHEMBL6633082 | 0.83 | NAMPT (0.40) | PTPN11NAMPTCYP17A1LMNARORC | |
| SCHEMBL12209853 | 0.83 | NAMPT (0.43) | PTPN11NAMPTCYP17A1PSMB8RORC | |
| SCHEMBL6035817 | 0.83 | ACHE (0.41) | PTPN11NAMPTCYP17A1LMNAGRM5 | |
| SCHEMBL1479189 | 0.82 | MAPT (0.49) | PTPN11NAMPTCYP17A1 | |
| SCHEMBL6600061 | 0.82 | LMNA (0.47) | PTPN11NAMPTCYP17A1LMNARORC | |
| SCHEMBL21605007 | 0.81 | EGLN2 (0.47) | NAMPTCYP17A1GRM5RORCEGLN2 | |
| SCHEMBL29996741 | 0.81 | EGLN2 (0.47) | NAMPTCYP17A1GRM5RORCEGLN2 | |
| SCHEMBL13529222 | 0.81 | PTPN11 (0.46) | PTPN11NAMPTCYP17A1RORC | |
| SCHEMBL14428036 | 0.80 | NAMPT (0.54) | NAMPTCYP17A1PSMB8RORCMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | PTPN11 973/4885NAMPT 1506/4885CYP17A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.